160 related articles for article (PubMed ID: 30325576)
21. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden.
Jönsson L; Bolinder B; Lundkvist J
Value Health; 2006; 9(3):193-8. PubMed ID: 16689714
[TBL] [Abstract][Full Text] [Related]
22. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
Alemayehu B; Liu J; Rajpathak S; Engel SS
J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD; Li Y; Leal J; Radican L; Adler AI; Alfredsson J; Buse JB; Green JB; Kaufman KD; Riefflin A; Van de Werf F; Peterson ED; Gray AM; Holman RR;
Diabetes Obes Metab; 2018 Jul; 20(7):1732-1739. PubMed ID: 29573215
[TBL] [Abstract][Full Text] [Related]
24. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products.
Bullano MF; Fisher MD; Grochulski WD; Menditto L; Willey VJ
Am J Health Syst Pharm; 2006 Dec; 63(24):2473-82. PubMed ID: 17158695
[TBL] [Abstract][Full Text] [Related]
25. Documented hypoglycemia is associated with poor short and long term prognosis among patients admitted to general internal medicine departments.
Leibovitz E; Khanimov I; Wainstein J; Boaz M
Diabetes Metab Syndr; 2019; 13(1):222-226. PubMed ID: 30641701
[TBL] [Abstract][Full Text] [Related]
26. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
[TBL] [Abstract][Full Text] [Related]
27. Cost and co-morbidities associated with hypoglycemic inpatients in Belgium.
Chevalier P; Vandebrouck T; De Keyzer D; Mertens A; Lamotte M
J Med Econ; 2016; 19(1):44-52. PubMed ID: 26428944
[TBL] [Abstract][Full Text] [Related]
28. Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults With Diabetes: Population-Based Modeling Study, 2011-2014.
Mahoney GK; Henk HJ; McCoy RG
Mayo Clin Proc; 2019 Sep; 94(9):1731-1742. PubMed ID: 31422897
[TBL] [Abstract][Full Text] [Related]
29. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
[TBL] [Abstract][Full Text] [Related]
30. Costs of managing severe hypoglycaemia in three European countries.
Hammer M; Lammert M; Mejías SM; Kern W; Frier BM
J Med Econ; 2009; 12(4):281-90. PubMed ID: 20001570
[TBL] [Abstract][Full Text] [Related]
31. Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: a retrospective study.
Khunti K; Fisher H; Paul S; Iqbal M; Davies MJ; Siriwardena AN
Prim Care Diabetes; 2013 Jul; 7(2):159-65. PubMed ID: 23375384
[TBL] [Abstract][Full Text] [Related]
32. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
33. The burden of severe hypoglycemia in type 1 diabetes.
Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
Curr Med Res Opin; 2018 Jan; 34(1):171-177. PubMed ID: 29019269
[TBL] [Abstract][Full Text] [Related]
34. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
35. Costs associated with emergency care and hospitalization for severe hypoglycemia.
Veronese G; Marchesini G; Forlani G; Saragoni S; Degli Esposti L; Centis E; Fabbri A;
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):345-51. PubMed ID: 26897390
[TBL] [Abstract][Full Text] [Related]
36. The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan.
Strizek A; Chang CJ; Furnback W; Wang B; Lebrec J; Lew T
Value Health Reg Issues; 2019 May; 18():84-90. PubMed ID: 30776767
[TBL] [Abstract][Full Text] [Related]
37. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
[TBL] [Abstract][Full Text] [Related]
38. Impact of the severity of hypoglycemia on health - Related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes.
Pawaskar M; Iglay K; Witt EA; Engel SS; Rajpathak S
J Diabetes Complications; 2018 May; 32(5):451-457. PubMed ID: 29496365
[TBL] [Abstract][Full Text] [Related]
39. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
40. Effect of Diabetes Treatment-Related Attributes on Costs to Type 2 Diabetes Patients in a Real-World Population.
Meng J; Casciano R; Lee YC; Stern L; Gultyaev D; Tong L; Kitio-Dschassi B
J Manag Care Spec Pharm; 2017 Apr; 23(4):446-452. PubMed ID: 28345434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
